Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

High rate of BA.1, BA.1.1 and BA.2 infection in triple vaccinated

Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Wanda Christ, Max Gordon, Henry Ng, Kim Blom, Mia Phillipson, Sara Mangsbo, Anna Smed Sörensen, Peter Nilsson, Sophia Hober, Mikael Åberg, Jonas Klingström, View ORCID ProfileCharlotte Thålin
doi: https://doi.org/10.1101/2022.04.02.22273333
Ulrika Marking
1Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Havervall
1Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nina Greilert Norin
1Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wanda Christ
2Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Max Gordon
1Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Ng
3Department of Medical Cell Biology and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Blom
1Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mia Phillipson
3Department of Medical Cell Biology and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sara Mangsbo
4Department of Pharmacy and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Smed Sörensen
5Division of Immunology and Allergy, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Nilsson
6Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sophia Hober
6Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikael Åberg
7Department of Medical Sciences, Clinical Chemistry and SciLifeLab, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonas Klingström
2Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charlotte Thålin
1Department of Clinical Sciences, Karolinska Institutet Danderyd Hospital, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Charlotte Thålin
  • For correspondence: charlotte.thalin{at}ki.se
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Booster vaccine doses offer protection against severe COVID-19 caused by omicron but are less effective against infection. Characteristics such as serological correlates of protection, viral abundance and clearance of omicron infections in triple vaccinated individuals are scarce.

Methods We conducted a 4-week twice-weekly SARS-CoV-2 qPCR screening shortly after an mRNA vaccine booster in 375 healthcare workers. Anti-Spike IgG levels and neutralization titers were determined at study start. qPCR-positive participants were sampled repeatedly for two weeks and monitored for symptoms.

Result In total 82 (cumulative incidence 22%) omicron infections were detected, divided between BA.1, BA.1.1 and BA.2. Only 10% of infected participants remained asymptomatic. Viral load peaked at day 3 and live virus could be detected for up to 9 days after first PCR-positive sample. Presence of symptoms correlated to elevated viral load (p<0.0001), but despite resolution of symptoms most participants showed Ct levels <30 at day 9. While post-booster antibody titers were similar in those with and without subsequent breakthrough infection (p>0.05), high antibody titers were linked to reduced viral load (p<0.01) and time to viral clearance (p<0.01). No significant differences were observed for viral load and time to viral clearance between BA.1, BA.1.1 and BA.2 infected individuals.

Conclusion We report high incidence of omicron infections despite recent booster vaccination in triple vaccinated individuals. Vaccine-induced antibody titres seem to play a limited role in risk of omicron infection. High viral load and secretion of live virus for up to nine days may increase transmission in a triple vaccinated population.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work has been funded by Jonas and Christina af Jochnick foundation (CT); Lundblad family foundation (CT); Region Stockholm (CT); Knut and Alice Wallenberg foundation (CT, JK); Jonas Soderquist scholarship (CT); Science for Life Laboratory (PN); Erling-Persson family foundation (SoH); Center for Innovative Medicine (JK, KB); and Swedish Research Council (JK).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Swedish Ethical Review Authority (dnr 2020-01653) and conducted in accordance with the declaration of Helsinki. Written informed consent was obtained from all study participants.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵# shared first authorship

  • ↵* shared senior autorship

Data Availability

All data produced in the present study are available upon reasonable request to the authors

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 03, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
High rate of BA.1, BA.1.1 and BA.2 infection in triple vaccinated
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
High rate of BA.1, BA.1.1 and BA.2 infection in triple vaccinated
Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Wanda Christ, Max Gordon, Henry Ng, Kim Blom, Mia Phillipson, Sara Mangsbo, Anna Smed Sörensen, Peter Nilsson, Sophia Hober, Mikael Åberg, Jonas Klingström, Charlotte Thålin
medRxiv 2022.04.02.22273333; doi: https://doi.org/10.1101/2022.04.02.22273333
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
High rate of BA.1, BA.1.1 and BA.2 infection in triple vaccinated
Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Wanda Christ, Max Gordon, Henry Ng, Kim Blom, Mia Phillipson, Sara Mangsbo, Anna Smed Sörensen, Peter Nilsson, Sophia Hober, Mikael Åberg, Jonas Klingström, Charlotte Thålin
medRxiv 2022.04.02.22273333; doi: https://doi.org/10.1101/2022.04.02.22273333

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (434)
  • Allergy and Immunology (760)
  • Anesthesia (222)
  • Cardiovascular Medicine (3316)
  • Dentistry and Oral Medicine (366)
  • Dermatology (282)
  • Emergency Medicine (480)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1175)
  • Epidemiology (13402)
  • Forensic Medicine (19)
  • Gastroenterology (900)
  • Genetic and Genomic Medicine (5181)
  • Geriatric Medicine (483)
  • Health Economics (786)
  • Health Informatics (3286)
  • Health Policy (1146)
  • Health Systems and Quality Improvement (1199)
  • Hematology (432)
  • HIV/AIDS (1024)
  • Infectious Diseases (except HIV/AIDS) (14657)
  • Intensive Care and Critical Care Medicine (917)
  • Medical Education (478)
  • Medical Ethics (128)
  • Nephrology (526)
  • Neurology (4957)
  • Nursing (263)
  • Nutrition (735)
  • Obstetrics and Gynecology (889)
  • Occupational and Environmental Health (797)
  • Oncology (2531)
  • Ophthalmology (730)
  • Orthopedics (284)
  • Otolaryngology (348)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (547)
  • Pediatrics (1308)
  • Pharmacology and Therapeutics (552)
  • Primary Care Research (559)
  • Psychiatry and Clinical Psychology (4224)
  • Public and Global Health (7526)
  • Radiology and Imaging (1716)
  • Rehabilitation Medicine and Physical Therapy (1022)
  • Respiratory Medicine (982)
  • Rheumatology (480)
  • Sexual and Reproductive Health (500)
  • Sports Medicine (425)
  • Surgery (551)
  • Toxicology (72)
  • Transplantation (237)
  • Urology (206)